Take position. Effect of SGLT2-i on blood pressure, vascular damage, kidney disease, and associated cardiovascular risk

Authors

  • Felipe Inserra Maimónides University, Autonomous City of Buenos Aires, Argentina
  • Ezequiel Forte Cardiovascular Diagnostic Center (CENDIC), Entre Ríos, Argentina
  • Alicia Elbert Metabolism Committee of the Argentine Society of Nephrology, Autonomous City of Buenos Aires, Argentina
  • Gabriel Waisman Argentine Society of Hypertension Arterial, Autonomous City of Buenos Aires, Argentina
  • Carlos Castellaro Austral University, Autonomous City of Buenos Aires, Argentina

DOI:

https://doi.org/10.47196/diab.v57i3.728

Keywords:

gliflozins, renal protection, cardiac protection, vascular protection, effects on cells and organelles

Abstract

A surprising new paradigm has been established with the advent of "gliflozins". Beyond their antihyperglycemic action, these drugs have significantly impacted the therapeutics of cardio-vascular-renal-metabolic disorders responsible for the most prevalent diseases we address in clinical practice. Sodium-glucose cotransporter type 2 (SGLT-2 i) inhibitors help control and reduce the progression of target organ damage.

In this Statement of Position, four of the Medical Societies linked to these issues agreed to reflect the knowledge of this hopeful phenomenon generated by more than 7,500 publications published in the last ten years on the benefit of "gliflozins". We decided to rigorously review the experimental evidence and the multiple controlled works showing its metabolic, vascular, cardiac, renal, and cellular effects, including unresolved aspects and warnings about the precautions in its use.

Author Biographies

Felipe Inserra, Maimónides University, Autonomous City of Buenos Aires, Argentina

Nephrologist, former president of the Argentine Society of Arterial Hypertension, member of the Committees on Renal Health and Arterial Hypertension and Vascular Damage, Argentine Society of Nephrology, Director of the Master's Degree in Vascular Mechanics and Arterial Hypertension, Universidad Austral, Doctor Honoris Causa

Ezequiel Forte, Cardiovascular Diagnostic Center (CENDIC), Entre Ríos, Argentina

Cardiologist, full member of the Argentine Society of Cardiology, Fellow of the Inter-American Society of Cardiology, Director of the Cardiometabolism Council of the Argentine Society of Cardiology, scientific advisor of the Obesity and Diabetes Committee of the Argentine Federation of Cardiology, Area Coordinator Community of the Inter-American Society of Cardiology, Medical Director at CENDIC

Alicia Elbert, Metabolism Committee of the Argentine Society of Nephrology, Autonomous City of Buenos Aires, Argentina

Nephrologist specialized in Diabetes, Director of the Center for Renal Disease and Arterial Hypertension (CEREHA), former associate research doctor of the Diabetology Division, Hospital de Clínicas José de San Martín, University of Buenos Aires (UBA), advisor to the Nephrology Committee of the Argentine Diabetes Society and the Metabolism Committee of the Argentine Society of Nephrology

Gabriel Waisman, Argentine Society of Hypertension Arterial, Autonomous City of Buenos Aires, Argentina

Internist, Full Professor, Master of Vascular Mechanics and Arterial Hypertension, Universidad Austral, Staff Physician at the Lezica Cardiovascular Institute, former head of the Medical Clinic Service and former head of Arterial Hypertension, Hospital Italiano de Buenos Aires, former president of the Argentine Society of Hypertension Arterial

Carlos Castellaro, Austral University, Autonomous City of Buenos Aires, Argentina

Nephrologist, Master in Arterial Hypertension, Nephrology Service of the Center for Medical Education and Clinical Research (CEMIC), Full Professor of Medicine at the University Institute (IUC, CEMIC), deputy director of the Master's Degree in Vascular Mechanics and Arterial Hypertension

References

I. Cherney DZ, Perkins BA, Soleymanlou N, Maione M, Lai V, Lee A, Fagan NM, Woerle HJ, Johansen OE, Broedl UC, von Eynatten M. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation. 2014 Feb 4;129(5):587-97. doi: 10.1161/CIRCULATIONAHA.113.005081.

II. Shin SJ, Chung S, Kim SJ, Lee EM, Yoo YH, Kim JW, Ahn YB, Kim ES, Moon SD, Kim MJ, Ko SH. Effect of sodium-glucose co-transporter 2 inhibitor, dapagliflozin, on renal renin-angiotensin system in an animal model of type 2 diabetes. PLoS One 2016 Nov 1;11(11):e0165703. doi: 10.1371/journal.pone.0165703.

III. Packer M. Critical reanalysis of the mechanisms underlying the cardiorenal benefits of SGLT-2 inhibitors and reaffirmation of the nutrient deprivation signaling/autophagy hypothesis. Circulation 2022 Nov;146(18):1383-1405. doi: 10.1161/CIRCULATIONAHA.122.061732.

IV. Theofilis P, Oikonomou E, Tsioufis K, Tousoulis D. Diabetes mellitus and heart failure: epidemiology, pathophysiologic mechanisms, and the role of SGLT-2 inhibitors. Life (Basel) 2023 Feb 10;13(2):497. doi: 10.3390/life13020497.

V. Kondo H, Akoumianakis I, Badi I, Akawi N, Kotanidis CP, Polkinghorne M, Stadiotti I, Sommariva E, Antonopoulos AS, Carena MC, et al. Effects of canagliflozin on human myocardial redox signalling: clinical implications. Eur Heart J 2021;42:4947-4960.

VI. Avogaro A, Fadini GP, Del Prato S. Reinterpreting cardiorenal protection of renal sodium-glucose cotransporter 2 inhibitors via cellular life history programming. Diabetes Care 2020 Mar;43(3):501-507. doi: 10.2337/dc19-1410.

VII. Tuttle KR. Digging deep into cells to find mechanisms of kidney protection by SGLT2 inhibitors. J Clin Invest 2023 Mar 1;133(5):e167700. doi: 10.1172/JCI167700.

VIII. Briasoulis A, Al Dhaybi O, Bakris GL. SGLT2 Inhibitors and mechanisms of hypertension. Curr Cardiol Rep 2018 Jan 19;20(1):1. doi: 10.1007/s11886-018-0943-5.

IX. Kim HK, Ishizawa R, Fukazawa A, Wang Z, Bezan-Petric U, Hu MC, Smith SA, Mizuno M, Vongpatanasin W. Dapagliflozin attenuates sympathetic and pressor responses to stress in young prehypertensive spontaneously hypertensive rats. Hypertension 2022 Aug;79(8):1824-1834.

X. Adam CA, Anghel R, Marcu DTM, Mitu O, Roca M, Mitu F. Impact of sodium-glucose cotransporter 2 (SGLT2) inhibitors on arterial stiffness and vascular aging. What do ee know so far? (a narrative review). Life (Basel) 2022 May 27;12(6):803. doi: 10.3390/life12060803.

XI. Trum M, Riechel J, Lebek S, Pabel S, Sossalla ST, Hirt S, Arzt M, Maier LS, Wagner S. Empagliflozin inhibits Na+/H+ exchanger activity in human atrial cardiomyocytes. ESC Heart Fail 2020 Dec;7(6):4429-4437. doi: 10.1002/ehf2.13024.

Downloads

Published

2023-12-12

How to Cite

Inserra, F., Forte, E., Elbert, A., Waisman, G., & Castellaro, C. (2023). Take position. Effect of SGLT2-i on blood pressure, vascular damage, kidney disease, and associated cardiovascular risk. Journal of the Argentine Society of Diabetes, 57(3). https://doi.org/10.47196/diab.v57i3.728

Issue

Vol. 57 No. 3 (2023): September-December

Section

Intersociety Document

License

Copyright (c) 2023 on behalf of the authors. Reproduction rights: Argentine Diabetes Society

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Dirección Nacional de Derecho de Autor, Exp. N° 5.333.129. Instituto Nacional de la Propiedad Industrial, Marca «Revista de la Sociedad Argentina de Diabetes - Asociación Civil» N° de concesión 2.605.405 y N° de disposición 1.404/13.

La Revista de la SAD está licenciada bajo Licencia Creative Commons Atribución – No Comercial – Sin Obra Derivada 4.0 Internacional.

Por otra parte, la Revista SAD permite que los autores mantengan los derechos de autor sin restricciones.